Generic Name

TiZANidine

Brand Names
Ontralfy, Tizandine, Tizanidne, Zanaflex
FDA approval date: July 03, 2002
Classification: Central alpha-2 Adrenergic Agonist
Form: Tablet, Capsule, Solution

What is Ontralfy (TiZANidine)?

Ontralfy is indicated for the treatment of spasticity in adults. Ontralfy is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity in adults.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures

Objective: To measure postoperative pain control in patients in two treatment arms of ORIF of the clavicle: a treatment group given a nonopioid pain control regimen, and a standard of care control group given standard opioid pain control regimen. Study

Effect of Neural Constraints on Movement in Stroke

Summary: This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in moveme...

Postoperative Tizanidine Use in Pelvic Reconstructive Surgery: A Pilot Study

Summary: The goal of this clinical trial is to evaluate whether adding tizanidine to the standard postoperative pain regimen improves recovery after pelvic reconstructive surgery in adult women. The main questions it aims to answer are: Does postoperative tizanidine improve patient-reported recovery 4-6 weeks after surgery? Does tizanidine reduce postoperative pain, opioid use, constipation, and healthcare...

Brand Information

    Ontralfy (Tizanidine Hydrochloride)
    1INDICATIONS AND USAGE
    Ontralfy is indicated for the treatment of spasticity in adults.
    2DOSAGE FORMS AND STRENGTHS
    Oral Solution: 2 mg/5 mL of tizanidine as a clear, colorless to pale yellow solution with a strawberry flavor.
    3CONTRAINDICATIONS
    Ontralfy is contraindicated in patients:
    • taking strong CYP1A2 inhibitors
    • with a history of hypersensitivity to tizanidine or the ingredients in Ontralfy. Symptoms have included anaphylaxis and angioedema
    4ADVERSE REACTIONS
    The following clinically significant adverse reactions are described elsewhere in other sections of the prescribing information:
    • Hypotension
    • Liver Injury
    • Sedation
    • Hallucinosis/Psychotic-Like Symptoms
    • Hypersensitivity Reactions
    • Withdrawal Adverse Reactions
    4.1Clinical Trials Experience
    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
    The safety of Ontralfy has been established from adequate and well-controlled studies of tizanidine tablets in adult patients with spasticity
    The safety of tizanidine has been evaluated in three double-blind, randomized, placebo-controlled clinical studies
    The most common adverse reactions (>10% of patients treated with tizanidine) reported in multiple dose, placebo-controlled clinical studies involving 264 patients with spasticity were dry mouth, somnolence/sedation, asthenia (weakness, fatigue and/or tiredness), and dizziness. Three-quarters of the patients rated the reactions as mild to moderate and one-quarter of the patients rated the reactions as being severe. These adverse reactions appeared to be dose related.
    Table 1 lists adverse reactions that were reported in greater than 2% of patients in three multiple dose, placebo-controlled studies who received tizanidine where the frequency in the tizanidine group was greater than the placebo group.
    Table 1:  Multiple Dose, Placebo-Controlled Studies Adverse Reactions Reported in >2% of Patients Treated with Tizanidine Tablets and Incidence Greater than Placebo
    * includes weakness, fatigue, and/or tiredness
    In the single dose, placebo-controlled study involving 142 patients with spasticity due to multiple sclerosis (Study 1)
    Table 2: Single Dose, Placebo-Controlled Study—Common Adverse Reactions Reported
    * includes weakness, fatigue, and/or tiredness
    4.2Postmarketing Experience
    The following adverse reactions have been identified during post approval use of tizanidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
    Cardiac Disorders: Ventricular tachycardia, decreased blood pressure
    Hepatobiliary Disorders: Hepatotoxicity
    Musculoskeletal and Connective Tissue Disorders: arthralgia
    Nervous System Disorders: Convulsion, paresthesia, tremor, muscle spasms
    Psychiatric Disorders: Hallucinations
    Skin and Subcutaneous Tissue Disorders: Stevens Johnson Syndrome, anaphylactic reaction
    5OVERDOSAGE
    A review of the safety surveillance database revealed cases of intentional and accidental tizanidine overdose. Some of the cases resulted in fatality and many of the intentional overdoses were with multiple drugs including CNS depressants. The clinical manifestations of tizanidine overdose were consistent with its known pharmacology. In the majority of cases a decrease in sensorium was observed including lethargy, somnolence, confusion and coma. Depressed cardiac function is also observed including most often bradycardia and hypotension. Respiratory depression is another common feature of tizanidine overdose.
    Should overdose occur, ensure the adequacy of an airway and monitor cardiovascular and respiratory function. Dialysis is not likely to be an efficient method of removing tizanidine from the body
    6DESCRIPTION
    Ontralfy contains tizanidine hydrochloride as the active ingredient, which is a central alpha2-adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole monohydrochloride. It has a molecular formula of C
    Chemical Structure
    Tizanidine hydrochloride is a white to off-white, fine crystalline powder, which is odorless or with a faint characteristic odor. Tizanidine hydrochloride is slightly soluble in water and methanol; solubility in water decreases as the pH increases.
    Ontralfy is supplied as an oral solution. Each 5 mL contains 2 mg tizanidine (equivalent to 2.29 mg tizanidine hydrochloride), and the inactive ingredients anhydrous citric acid, edetate disodium dihydrate, flavor, methylparaben sodium, propylparaben sodium, purified water, sodium citrate anhydrous, and sucralose. Each 5 mL of Ontralfy contains 2 mg of sodium.
    7CLINICAL STUDIES
    The efficacy of Ontralfy is supported by evidence from a relative bioavailability study in healthy adult subjects comparing Ontralfy to tizanidine tablets under fasted and fed conditions
    The efficacy of tizanidine for the treatment of spasticity was demonstrated in two adequate and well-controlled studies in patients with multiple sclerosis or spinal cord injury (Studies 1 and 2).
    8PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label
    NDC 69528-310-16
    Ontralfy™
    16 fl. oz. (473 mL)
    bottle label